Searchable abstracts of presentations at key conferences in endocrinology

ea0038cmw3.1 | Workshop 3: Biological therapies - cause and cure of endocrine diseases | SFEBES2015

The thyroid and rituximab

Salvi Mario

Since our first report on successful treatment of one patient with moderate-severe GO in 2006, several non-controlled studies have suggested that RTX can be more effective in active GO than intravenous methylprednisolone (ivMP). One randomised controlled trial comparing RTX to placebo and one comparing RTX to steroids in moderate-severe GO were recently published.We have randomised 32 patients with active moderate-severe GO to be treated with RTX or ivMP...

ea0035s10.1 | Difficulties in the treatment of Graves orbitopathy | ECE2014

New therapeutic approach in Graves’ orbitopathy

Salvi Mario

There is preliminary evidence that B cell depletion with rituximab (RTX), a chimeric mouse-human monoclonal antibody directed against the CD 20 antigen on B lymphocytes, may be effective for the treatment of moderate-severe Graves’ orbitopathy (GO). While mostly non-controlled studies have shown that this modality of immunosuppression has potential in the therapy of moderate–severe GO, in particular for the control of the active, inflammatory phase of the disease. Th...

ea0032mte6 | (1) | ECE2013

New immunotherapy approaches for Graves’ orbitopathy

Salvi Mario

The role of B-cell in human autoimmune disease have recently been emphasized due to the therapeutic benefit of B-cell depleting therapies. B cells are involved in the production of autoantibodies, CD4+T-cell activation and control of T-cell function and inflammation, through cytokine production. Although autoantibodies alone may not initiate autoimmune disease, their relationship with the disease course suggests that they are a key factor contributing to the mechanisms of dise...

ea0073mte1 | Meet The Expert 1: New therapies in the treatment of thyroid ophthalmopathy | ECE2021

New therapies in the treatment of thyroid ophthalmopathy

Salvi Mario

IntroductionMedical immunosuppressive treatment of Graves’ orbitopathy (GO) is advised for patents with moderate-severe disease. Steroids represent the mainstay of therapy, as they possess anti-inflammatory activity, but about 20 – 30% of patients are unresponsive and up to 20% of patients may relapse. Immunosuppressive therapeutics alternative to corticosteroids are those targeting the different antigens involved in the pathogenic reactions of...

ea0081p200 | Thyroid | ECE2022

Thyroid dysfunction related to SARS-CoV-2 vaccination: the experience of a single center in Milan

Muller Ilaria , Di Marco Francesco , Arosio Maura , Salvi Mario

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic disease (Covid-19) has caused millions of deaths worldwide, thus a massive SARS-CoV-2 vaccination campaign has been launched since the end of 2020. Viruses and vaccines can induce adverse thyroid effects; SARS-CoV-2 infection and vaccines have been associated with several thyroid disorders, especially subacute thyroiditis (SAT) and Graves’ disease (GD). We aimed to study the occurrence o...

ea0022p816 | Thyroid | ECE2010

A single small dose of rituximab may be effective in Graves' orbitopathy

Covelli Danila , Vannucchi Guia , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

The anti-CD 20 antibody rituximab (RTX) has been employed in the treatment of several autoimmune diseases and its effect may not involve autoantibody secretion. Preliminary studies have shown that RTX induced improvement of active Graves’ orbitopathy (GO) but caused no change of serum anti-thyroid antibodies in relation to peripheral CD 20+ cells depletion, usually observed at the second week after therapy. A 50-year-old woman with GO predominantly active in the left eye ...

ea0020p120 | Thyroid | ECE2009

Seasonal occurrence of Graves’ disease and associated orbitopathy at diagnosis

Campi Irene , Vannucchi Guia , Covelli Danila , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

A seasonal occurrence of Graves’ disease (GD) has been reported in previous studies, with a peak of frequency in the warmer half of the year (Ford 1988, 1991, Westphal 1994) or the period of the year with a higher iodine intake (Phillips 1985); other studies (Facciani 2000) have failed to find a different seasonal occurrence of Graves’ orbitopathy (GO). Aim of the present study was to evaluate a possible seasonal difference in the onset of GD and GO in a series of ou...

ea0084ps1-01-08 | COVID & Thyroid Disease | ETA2022

Graves’ orbitopathy and subacute thyroiditis related to SARS-CoV-2 infection or vaccination: the experience of a single centre in milan, italy

Muller Ilaria , Crivicich Erica , Di Marco Francesco , Curro Nicola , Arosio Maura , Salvi Mario

Background: The Covid-19 pandemic caused by the severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) determined millions of deaths worldwide, thus at the end of 2020 a massive vaccination campaign has been launched. SARS-CoV-2 infection and vaccines have been associated with several thyroid disorders, especially subacute thyroiditis (SAT), Graves’ disease (GD) and orbitopathy (GO). We studied the occurrence of SAT and GO following SARS-CoV-2 infection or vaccinati...

ea0084ps3-12-112 | Graves’ Disease 2 and Orbitopathy | ETA2022

Alemtuzumab-induced graves’ orbitopathy successfully treated with a single dose of rituximab

Di Marco Francesco , Porcaro Laura , Crivicich Erica , Curro Nicola , Arosio Maura , Muller Ilaria , Salvi Mario

Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves’ disease (GD) accounting for 63-65% of cases. Graves’ Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...

ea0063gp81 | Thyroid Autoimmune Disorders | ECE2019

Retrospective analysis of the efficacy of three different dose regimens of rituximab in patients with active moderate-severe graves’ orbitopathy

Lazzaroni Elisa , Covelli Danila , Campi Irene , Vannucchi Guia , Curro Nicola , Pirola Giacinta , Guastella Claudio , Dolci Alessia , Arosio Maura , Salvi Mario

Aim: The aim of this retrospective study was to assess the efficacy of different doses of rituximab (RTX) in patients with active moderate-severe Graves’ Orbitopathy (GO).Methods: Overall 40 patients, 5 M/35 F; mean age (± S.D.) 58±11 years were treated with RTX; 21 were smokers. The patients received the following treatment: 14 patients (group 1) a single 100 mg dose; 15 patients (group 2) a single 500 mg dose and 11 Patien...